The prevalence of TERT promoter mutations reported in the literature ranged from 7.3 to 25.5 % in PTC and from 4.3 to 36.4 % in FTC [17, 18, 21, 24, 25, 32, 37–43]. This evidence concerns the gene TERT and thyroid cancer, nonmedullary, 2.